vVARDIS Holding AG (New York Stock Exchange:VVVV)
| Market Cap | $338.45M+0.0% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 20.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,780,891 |
| Open | $14.00 |
| Previous Close | $18.00 |
| Day's Range | $14.00 - $16.50 |
| 52-Week Range | $14.00 - $18.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VVVV
vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel. The company was incorporated in 2020 and is based in Zug, Switzerland. vVARDIS Holding AG operates as a subsidiary of VVARDIS Investment Holding AG.
$VVVV stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VVVV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VVVV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VVVV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VVVV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VVVV from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from VVVV’s recent data — informational, not investment advice
What’s Behind the Score
News check: IPO announcement and capital raise are factually positive, but stock debuted below IPO price, creating mixed near-term sentiment.